MaxCyte Inc [MXCT] stock is trading at $4.40, down -3.72%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MXCT shares have gain 6.02% over the last week, with a monthly amount glided 5.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MaxCyte Inc [NASDAQ: MXCT] stock has seen the most recent analyst activity on November 29, 2023, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $7. On August 24, 2021, William Blair initiated with a Outperform rating. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $36 on August 24, 2021. Stifel initiated its recommendation with a Buy and recommended $18 as its price target on August 24, 2021. Stephens started tracking with a Overweight rating for this stock on August 24, 2021, and assigned it a price target of $19. In a note dated August 24, 2021, Cowen initiated an Outperform rating.
MaxCyte Inc [MXCT] stock has fluctuated between $3.16 and $5.55 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. MaxCyte Inc [NASDAQ: MXCT] shares were valued at $4.40 at the most recent close of the market. An investor can expect a potential return of 81.82% based on the average MXCT price forecast.
Analyzing the MXCT fundamentals
MaxCyte Inc [NASDAQ:MXCT] reported sales of 45.60M for the trailing twelve months, which represents a growth of 1.99%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -1.02%, Pretax Profit Margin comes in at -0.78%, and Net Profit Margin reading is -0.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.16 and Total Capital is -0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.26 points at the first support level, and at 4.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.50, and for the 2nd resistance point, it is at 4.60.
Ratios To Look Out For
For context, MaxCyte Inc’s Current Ratio is 9.81. Further, the Quick Ratio stands at 9.22, while the Cash Ratio is 2.1. Considering the valuation of this stock, the price to sales ratio is 10.18, the price to book ratio is 2.17.
Transactions by insiders
Recent insider trading involved Johnston John Joseph, Director, that happened on Dec 26 ’24 when 3000.0 shares were sold. Affiliate, Johnston John Joseph completed a deal on Dec 26 ’24 to buy 12000.0 shares. Meanwhile, Director Johnston John Joseph sold 2495.0 shares on Dec 09 ’24.
